Massachusetts state officials have put a record $40 million package on the table to keep Insulet Corp., the maker of the Omnipod insulin delivery system, in Massachusetts. Insulet's headquarters and manufacturing operations are in Acton. Officials described it as their most aggressive job creation package yet, a sign of how seriously the state is fighting to hold onto one of its marquee medical device employers.
The offer, reported by NBC Boston, comes amid Insulet's global growth. The company was founded in Massachusetts in 2000 by John Brooks, whose son was diagnosed with type 1 diabetes that same year, and it now employs 5,400 people worldwide. Insulet makes automated insulin delivery systems and is headquartered in Acton, where it has built its manufacturing base.
The state has a broader life-sciences incentive program under the Mass Leads Act. The offer signals the weight officials are putting behind keeping Insulet in Massachusetts.
Local Incentives Already in Place
The state package builds on incentives already approved closer to home. In May, Acton Town Meeting approved a Tax Increment Financing agreement to support Insulet's expansion into 35 Nagog Park, according to The Acton Exchange. That agreement builds on a 2017 TIF deal that originally helped bring Insulet's headquarters and manufacturing operations to town, when the company converted a building that had sat vacant for 15 years into its global headquarters.
Insulet has continued investing in that campus over the years. Back in 2020, the company installed approximately 2,800 rooftop solar panels across its Acton headquarters and manufacturing complex — part of a broader pattern of local capital investment that state and town officials are now hoping to keep from shifting overseas.
A Company Expanding Well Beyond Massachusetts
The urgency behind the state's offer is tied to Insulet's global ambitions. The company has also grown its international sales as part of its global growth.
Despite that overseas expansion, Insulet's workforce remains substantial. The company employs 5,400 people worldwide. Insulet reported full-year 2025 revenue of approximately $2.7 billion, up roughly 30% year over year, according to the company's SEC filings.
Recalls and Legal Pressure Cloud the Picture
That financial strength has come alongside real operational headaches. In May, Insulet initiated a voluntary correction affecting roughly 7 million Omnipod patch pumps — about 8.5% of its annual global production — due to cannula tubing leak risks, per MedTech Dive. It was the second major tubing-related correction the company issued in early 2026.
Insulet disclosed in SEC filings that it expects to incur up to $40 million in costs during 2026 to resolve the Omnipod 5 corrections. Following the recall, shareholders filed a federal securities class action lawsuit alleging Insulet misstated the adequacy of its manufacturing controls.
Insulet has also faced setbacks on the intellectual property front. A federal appeals court in May overturned a $59.4 million trade secret judgment the company had won against rival EOFlow, ruling that Insulet had missed the three-year statute of limitations to bring the claim, MedTech Dive reported.
Taken together, the recalls, litigation, and legal reversal complicate what is otherwise a growth story for Insulet — and they help explain why Massachusetts is moving aggressively to retain the company in the state, as Insulet maintains its headquarters and manufacturing operations in Acton. Hoodline has previously covered the broader push toward automated insulin delivery integration that continues to drive demand for devices like the Omnipod 5.
